| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Repayment of notes payable | 0 | - |
| Net cash provided by (used in) financing activities | 1,241 | 1,180 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 16,845 | 14,586 |
| Cash and cash equivalents at beginning of period | 39,461 | - |
| Cash and cash equivalents at end of period | 56,306 | - |
Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. (MCRB)